Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca bez komórek płaskich (typ nie-płaskonabłonkowy) z określonym profilem genetycznym EGFR
- •Rak endometrium (nowotwór wyściółki macicy)
- •Oporny na platynę rak jajnika
- •Zaawansowany lub przerzutowy nowotwór litych z potwierdzonym białkiem PTK7
✗ Disqualifies
- •Przerzuty do mózgu, które nie są kontrolowane
- •Historia zapalenia opon mózgowych spowodowanego rakiem
- •Aktywna, niekontrolowana infekcja (bakteryjna, wirusowa, grzybiczna)
- •Problemy ze rogówką oka lub przeszczep rogówki w przeszłości
- •Poważne działania niepożądane z poprzednich terapii
- •Znaczące choroby serca
- •Wydłużony czas QTcF w EKG (≥470 milisekund)
- •Historia zapalenia płuc lub choroby śródmiąższowej płuc
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (12)
University of Arkansas
Little Rock, United States
UCLA - Hematology/Oncology Clinical Research Unit
Los Angeles, United States
St. Francis Medical Center (OSF Healthcare)
Peoria, United States
START - Midwest
Grand Rapids, United States
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, United States
Roswell Park Comprehensive Care Center
Buffalo, United States
University Hospital - Cleveland Medical Center
Cleveland, United States
NEXT Oncology - Austin
Austin, United States
NEXT - Oncology - Houston
Houston, United States
START - San Antonio
San Antonio, United States
NEXT Oncology - Virginia Cancer Specialists
Fairfax, United States
Fred Hutchinson Cancer Center
Seattle, United States
Trial contact
Clinical Trial Manager Lead
Central email mailbox - Whitehawk Therapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.